Abstract
We read with interest the article by Lipsky and Barrett and concur that intracameral moxifloxacin is a safer and more efficacy alternative to vancomycin as evidence emerges of postoperative haemorrhagic occlusive retinal vasculitis (HORV) associated with vancomycin.1 However we wish to redress the point stated about lack of avilability in Australia. Moxifloxacin is available in Australia for preparation into intracameral formulation. In our centre, when managing patients with penicillin or β-lactam allergy, we have ceased using vancomycin and now routinely administer intracameral moxifloxacin. We report the steps undertaken to implement this change in our care pathway.
| Original language | English |
|---|---|
| Pages (from-to) | 137-139 |
| Number of pages | 3 |
| Journal | Clinical and Experimental Ophthalmology |
| Volume | 48 |
| Issue number | 1 |
| Early online date | 1 Oct 2019 |
| DOIs | |
| Publication status | Published - Jan 2020 |
Bibliographical note
This author accepted manuscript is made available following 12 month embargo from date of publication (October 2019) in accordance with the publisher’s archiving policy"This is the peer reviewed version of the following article: Phillips, C. J., & Mills, R. A. (2019). Intracameral antibiotics for prophylaxis of postoperative endophthalmitis in Australia: Comment. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.13645, which has been published in final form at https://doi.org/10.1111/ceo.13645. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions."
Keywords
- antibiotics
- ophthalmology
- postoperative endophthalmitis
- Comment
- Letter to the editor